Heidelberg (ots) – SYGNIS reports financial results for fiscal year 2012
– Strategic realignment completed – discontinuation of drug
– New business model shows first commercial success
– Progress in restructuring and cost saving
SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today reported results for the fiscal year 2012 ending on December 31, 2012. The reverse acquisition of X-Pol Biotech led to a change in the fiscal year. Due to the business combination the new SYGNIS includes the total income and expenses of X-Pol for 2012 and those of old SYGNIS only for December 2012, which affects equity in the fully consolidated balance sheet accordingly. In addition, the prior year figures published relate to X-Pol Biotech fiscal year 2011, due to accounting requirements based on the reverse acquisition. Thus, the changes in financial statements primarily result from the purchase price allocation and the recognition of fair values of the old SYGNIS, while values of X-Pol products are reflected in the balance sheet only with their carrying amounts and not with their fair values. The comparability of the financial results reported with the corresponding prior-year data is therefore very limited.
In 2012, SYGNIS was focussed on the strategic realignment. In this context, activities in the area of drug development for diseases of the central nervous system have been stopped and extensive restructuring measures were initiated to significantly reduce the Company’s cost basis. As a result of the business combination with the Spanish company X-Pol Biotech, which was successfully completed in December 2012, SYGNIS now owns an entirely new business model focussed on the development and marketing of novel technologies in the area of molecular diagnostics, e.g. in DNA amplification and sequencing. In July 2012, SYGNIS granted an exclusive global license to QIAGEN N.V. for the key product QualiPhi®, an improved polymerase for amplifying DNA. On this basis the Company received a one-time payment and will receive sales-dependent royalties. First revenues are expected in 2013.
Pilar de la Huerta, CEO / CFO, commented: “The fiscal year 2012 of SYGNIS was marked by the successful business combination of SYGNIS and X-Pol Biotech. As a consequence, important steps for the future and restructuring measures were taken that have already been implemented. We were able also, to show first commercial success. We are delighted to have signed an exclusive worldwide license agreement with the market leader QIAGEN for our flagship product QualiPhi®. We will generate first revenues in the current year and plan break-even in fiscal year 2014.”
In financial year 2012, the reported loss for the period was -EUR2.4 million (previous year: -EUR0.9 million). The decrease primarily resulted from impairments of intangible assets of EUR1.0 million (previous year: EUR0.0 million) which were necessary due to a lack of probability of the future commercialisation of assets for various projects of X-Pol Biotech. Furthermore, operating expenses of old SYGNIS are included for December. R&D expenses increased to EUR1.0 million (previous year: EUR0.5 million). Revenue was EUR0.2 million (previous year: EUR0.0 million), mainly resulting from the marketing of QualiPhi®.
Total assets rose from EUR2.2 million to EUR9.6 million, primarily due to the goodwill resulting from the business combination of EUR5.9 million, as the market value of the old SYGNIS was higher than the fair values of its assets at the acquisition date. In addition, other intangible assets increased from EUR1.1 million to EUR2.3 million. Here the major effects were the development program DoubleSwitch and the Caco2 licence business, both capitalized on the old SYGNIS business. Equity was strengthened accordingly by EUR5.8 million to EUR6.3 million.
Cash outflow from operating activities was up from EUR0.6 million in the previous year to EUR1.3 million. This was especially due to the higher net loss for the period which was partly offset by increased amortization and imparments of intangible assets. Cash inflow from investing activities rose to EUR0.5 million (previous year: cash outflow of EUR0.7 million), primarily according to the cash inflow based on the reverse acquisition of EUR0.5 million. Based on a lower raising of non-current loans, cash flow from financing activities was reduced to EUR0.5 million (previous year: EUR1.9 million).
At the end of the period, cash and cash equivalents were EUR0.5 million (previous year: EUR0.9 million).
Apart from the already mentioned licensing deal, SYGNIS expects further commercial agreements with partners. At the same time the Company expects first revenues from product sales in the current fiscal year. In the mid-term, at least two new products shall be licensed annually in regional or global partnerships. The Company plans to reach break-even in fiscal year 2014. Based on extraordinary burdens from restructuring measures, the fiscal year 2013 will still show a loss. However, the Company assumes that current cost saving measures will lead to significant effects in the course of the year.
Available liquidity as of December 31, 2012 amounted to EUR0.5 million. Up to date, financing of current activities is secured by a shareholder loan until mid 2013. For further financing and thus the continuation, the Company is dependent on new funding from mid 2013 on. These shall be granted by new investors, further loans or by using the existing SEDA agreement.
Key financial figures for the fiscal 2012 ended December 31, 2012 and corresponding figures (IFRS)
Numbers in EURmillion 2012 2011
Revenues 0.2 –
Total expenses 2.6 0.9
EBIT -2.4 -0.9
Net results for the period -2.4 -0.9
Goodwill 5.9 –
Other intangible assets 2.3 1.1
Liquidity at year-end 0.5 0.9
Equity 6.3 0.5
(equity ratio in %) (65.6) (24.4)
Long-term financial liabilities 1.1 0.7
Operating Cash Flow -1.3 -0.6
SYGNIS will hold a conference call today to present the financial results for fiscal year 2012.
Details of the telephone conference:
Date: April 30, 2013
Time: 03.00 pm CET (02:00 pm GMT; 09:00 am EST)
Participant Dial In Number(s) Germany: +49-69-7104 45598
Spain: +34-91-788 9854
UK: +44-20-3003 2666
US: +1-866-966 5335 (Toll Free)
Please dial in 10 minutes before the beginning of the conference. For further information please contact:
SYGNIS Pharma AG
Pilar de la Huerta CEO/CFO
About SYGNIS Pharma AG: www.sygnis.de
After the merger in 2012 between X-Pol Biotech, specialising in DNA amplification and sequencing, and SYGNIS Pharma AG, listed in the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS’ new mission is to develop and distribute technologies and products from X-Pol, which has a commercial product in the DNA amplification segment, QualiPhi® and is currently developing other products in the field of Next Generation Sequencing.
### Disclaimer Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###
SYGNIS Pharma AG
Pilar de la Huerta